Moderna and Merck today presented results from a phase 2b trial evaluating the combination of mRNA-4157 (V940) with Keytruda in patients with resected high-risk melanoma (stage III/IV) after complete resection.

With a median follow-up of around three years (34.9 months), V940 + Keytruda delivered 'a clinically significant and durable improvement in recurrence-free survival', the study's primary endpoint, reducing the risk of recurrence or death by 49% compared to Keytruda alone.

In addition, V940 + Keytruda showed a significant improvement in distant metastasis-free survival (DMFS), a key secondary endpoint of the study, compared with Keytruda alone, reducing the risk of developing distant metastases or death by 62%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.